Caplin Point Laboratories Limited (BOM:524742)

India flag India · Delayed Price · Currency is INR
2,050.45
+27.00 (1.33%)
At close: Feb 20, 2025
31.20%
Market Cap 154.31B
Revenue (ttm) 18.90B
Net Income (ttm) 5.15B
Shares Out 76.01M
EPS (ttm) 67.45
PE Ratio 30.10
Forward PE 26.80
Dividend 5.00 (0.25%)
Ex-Dividend Date Sep 23, 2024
Volume 2,118
Average Volume 10,129
Open 2,036.25
Previous Close 2,023.45
Day's Range 2,008.60 - 2,067.00
52-Week Range 1,221.00 - 2,636.00
Beta 0.38
RSI 45.61
Earnings Date Feb 7, 2025

About Caplin Point Laboratories

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point La... [Read more]

Industry Pharmaceutical Preparations
Founded 1990
Employees 3,406
Stock Exchange Bombay Stock Exchange
Ticker Symbol 524742
Full Company Profile

Financial Performance

In 2023, Caplin Point Laboratories's revenue was 16.96 billion, an increase of 15.51% compared to the previous year's 14.68 billion. Earnings were 4.57 billion, an increase of 21.48%.

Financial Statements

News

Caplin Point Laboratories Q3 FY25 Results: Revenue up 13% YoY to Rs 493 crore, Net Profit up 17% YoY

Caplin Point Laboratories reported a solid performance for the quarter ending December 31, 2024, with key financial indicators showing significant growth. Revenue from Operations: ₹492.96 crore, a YoY...

16 days ago - Business Upturn

Caplin Point Laboratories subsidiary secures USFDA approval for Procainamide Hydrochloride Injection

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Procainamide Hydrochloride In...

18 days ago - Business Upturn

Caplin Point Laboratories subsidiary gets USFDA nod for Levetiracetam in sodium chloride injection

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited (BSE: CAPPL, NSE: CAPLIPOINT), has received final approval from the United States Food and Drug Administration (USFDA) for it...

5 weeks ago - Business Upturn

Caplin Point receives zero 483 observation from USFDA in recent inspection

Caplin Point Laboratories Limited announced that its subsidiary, Caplin Steriles Limited, received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA). The unan...

6 weeks ago - Business Upturn

Stock Market Update, December 27: Oberoi Realty, Caplin Point Laboratories and Jubilant FoodWorks hit 52-week highs today

The Indian stock market continued its positive momentum today, with benchmark indices showing modest gains. The Sensex rose by 226.59 points, or 0.29%, closing at 78,699.07, while the Nifty 50 gained ...

2 months ago - Business Upturn

Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion

Caplin Point Laboratories announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05...

2 months ago - Business Upturn

Caplin Point Laboratories shares hit new 52-week high this week; Check details

Caplin Point Laboratories shares made headlines this week by reaching a new 52-week high of ₹2,200.00 on November 29, 2024. The stock displayed impressive performance, supported by strong investor int...

3 months ago - Business Upturn

Caplin Point Laboratories shares up 2% after strong Q2 performance

Caplin Point Laboratories has reported its financial results for the second quarter of FY25, showing impressive year-over-year (YoY) growth in both revenue from operations and net profit. Financial Hi...

3 months ago - Business Upturn

Caplin Point Laboratories Q2 FY25 Results: Revenue rises 17.8% YoY to ₹483.10 crore, net profit up 12.7% YoY

Caplin Point Laboratories has announced its financial performance for the second quarter of FY25, showcasing notable growth in revenue from operations and net profit year-over-year (YoY). Financial Hi...

3 months ago - Business Upturn

Top losers today: NMDC, Tata Steel, Finolex, Caplin Point, JSW Steel, and Jindal Steel lead declines

In early trade today, several stocks have posted significant losses, with metals and industrial sectors taking a hit. Here is a look at the top losers as of 9:44 AM: NMDC Ltd: ₹215.39 (-5.84%) Tata St...

4 months ago - Business Upturn

Caplin Point Laboratories surges 6.77%, stock trading over ₹2025

Shares of Caplin Point Laboratories saw a significant rise, gaining 6.77% to trade at ₹2,026.40 as of 12:04 PM today. The stock opened at ₹1,900.00 and reached a high of ₹2,036.45, with a low of ₹1,89...

5 months ago - Business Upturn

Caplin Point shares hit 52-week high, surge over 7%

As of 9:58 AM, the stock was trading at ₹2,107.55, marking a significant increase of ₹138.70 or 7.04% from its previous close. This surge propelled the stock to breach its previous 52-week high, setti...

6 months ago - Business Upturn

Caplin Point shares surge 5% after Brazilian regulator clears Tamil Nadu facility

Caplin Point Laboratories’ shares saw a significant rise of over 5% after the Brazilian Health Regulatory Agency (ANVISA) gave a green light to the company’s manufacturing facility in Tamil Nadu. The ...

6 months ago - Business Upturn